ABSTRACT
OBJECTIVE: To evaluate the effect of different solutions administered to patients undergoing stem cell transplantation on oral mucositis. METHODS: The non-randomised controlled trial was conducted at a Istanbul Medipol Mega university hospital in Turkey between May 2014 and June 2016, and comprised patients undergoing stem cell transplantation. They were divided into three groups. Group 1 had patients using chlorhexidine gluconate and benzydamine hydrochloride solution. Group 2 had those using calcium and phosphate solution. Group 3 patients were using black mulberry syrup. Data was collected using a structured questionnaire and the World Health Organisation mucositis assessment scale. Assessment was done on days 7, 14 and 21. Clinical significance of oral solutions was statistically determined. RESULTS: Of the 83 patients, 30(36%) were in group 1, 28(34%) in group 2, and 25(30%) in group 3. On day 7, there was no significant difference in terms of grades among the groups (p>0.05). On day 14, grade 2 mucositis was seen in 2(8%) patents in group 3, 5(17.9%) in group 2 and 5(16.7%) in group 1; Grade 3 mucositis was seen in 2(6.7%) patients in group 1, but none in the other two groups. On day 21, grade 3 mucositis was present in 2(8.0%) in group 3, 2(7.1%) in group 2, and 4(13.3%) in group 1. CONCLUSIONS: The use of black mulberry and calcium-phosphate solutions was found to be beneficial in preventing and treating oral mucositis.
Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Neoplasms/therapy , Pharmaceutical Solutions/therapeutic use , Stomatitis/drug therapy , Adolescent , Adult , Aged , Benzydamine/therapeutic use , Chlorhexidine/analogs & derivatives , Chlorhexidine/therapeutic use , Female , Humans , Male , Middle Aged , Morus , Phosphates/therapeutic use , Plant Extracts/therapeutic use , Turkey , Young AdultABSTRACT
BACKGROUND: Ear wax (cerumen) is a normal bodily secretion that can become a problem when it obstructs the ear canal. Symptoms attributed to wax (such as deafness and pain) are among the commonest reasons for patients to present to primary care with ear trouble.Wax is part of the ear's self-cleaning mechanism and is usually naturally expelled from the ear canal without causing problems. When this mechanism fails, wax is retained in the canal and may become impacted; interventions to encourage its removal may then be needed. Application of ear drops is one of these methods. Liquids used to remove and soften wax are of several kinds: oil-based compounds (e.g. olive or almond oil); water-based compounds (e.g. sodium bicarbonate or water itself); a combination of the above or non-water, non-oil-based solutions, such as carbamide peroxide (a hydrogen peroxide-urea compound) and glycerol. OBJECTIVES: To assess the effects of ear drops (or sprays) to remove or aid the removal of ear wax in adults and children. SEARCH METHODS: We searched the Cochrane ENT Trials Register; Cochrane Register of Studies; PubMed; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the most recent search was 23 March 2018. SELECTION CRITERIA: Randomised controlled trials (RCTs) in which a 'cerumenolytic' was compared with no treatment, water or saline, an alternative liquid treatment (oil or almond oil) or another 'cerumenolytic' in adults or children with obstructing or impacted ear wax. DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. The primary outcomes were 1) the proportion of patients (or ears) with complete clearance of ear wax and 2) adverse effects (discomfort, irritation or pain). Secondary outcomes were: extent of wax clearance; proportion of people (or ears) with relief of symptoms due to wax; proportion of people (or ears) requiring further intervention to remove wax; success of mechanical removal of residual wax following treatment; any other adverse effects recorded and cost. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics. MAIN RESULTS: We included 10 studies, with 623 participants (900 ears). Interventions included: oil-based treatments (triethanolamine polypeptide, almond oil, benzocaine, chlorobutanol), water-based treatments (docusate sodium, carbamide peroxide, phenazone, choline salicylate, urea peroxide, potassium carbonate), other active comparators (e.g. saline or water alone) and no treatment. Nine of the studies were more than 15 years old.The overall risk of bias across the 10 included studies was low or unclear. PRIMARY OUTCOME: proportion of patients (or ears) with complete clearance of ear waxSix studies (360 participants; 491 ears) contributed quantitative data and were included in our meta-analyses.Active treatment versus no treatmentOnly one study addressed this comparison. The proportion of ears with complete clearance of ear wax was higher in the active treatment group (22%) compared with the no treatment group (5%) after five days of treatment (risk ratio (RR) 4.09, 95% confidence interval (CI) 1.00 to 16.80); one study; 117 ears; NNTB = 8) (low-quality evidence).Active treatment versus water or salineWe found no evidence of a difference in the proportion of patients (or ears) with complete clearance of ear wax when the active treatment group was compared to the water or saline group (RR 1.47, 95% CI 0.79 to 2.75; three studies; 213 participants; 257 ears) (low-quality evidence). Two studies applied drops for five days, but one study only applied the drops for 15 minutes. When we excluded this study in a sensitivity analysis it did not change the result.Water or saline versus no treatmentThis comparison was only addressed in the single study cited above (active versus no treatment) and there was no evidence of a difference in the proportion of ears with complete wax clearance when comparing water or saline with no treatment after five days of treatment (RR 4.00, 95% CI 0.91 to 17.62; one study; 76 ears) (low-quality evidence).Active treatment A versus active treatment BSeveral single studies evaluated 'head-to-head' comparisons between two active treatments. We found no evidence to show that one was superior to any other.Subgroup analysis of oil-based active treatments versus non-oil based active treatmentsWe found no evidence of a difference in this outcome when oil-based treatments were compared with non-oil-based active treatments. PRIMARY OUTCOME: adverse effects: discomfort, irritation or painOnly seven studies planned to measure and did report this outcome. Only two (141 participants;176 ears) provided useable data. There was no evidence of a significant difference in the number of adverse effects between the types of ear drops in these two studies. We summarised the remaining five studies narratively. All events were mild and reported in fewer than 30 participants across the seven studies (low-quality evidence).Secondary outcomesThree studies reported 'other' adverse effects (how many studies planned to report these is unclear). The available information was limited and included occasional reports of dizziness, unpleasant smell, tinnitus and hearing loss. No significant differences between groups were reported. There were no emergencies or serious adverse effects reported in any of the 10 studies.There was very limited or no information available on our remaining secondary outcomes. AUTHORS' CONCLUSIONS: Although a number of studies aimed to evaluate whether or not one type of cerumenolytic is more effective than another, there is no high-quality evidence to allow a firm conclusion to be drawn and the answer remains uncertain.A single study suggests that applying ear drops for five days may result in a greater likelihood of complete wax clearance than no treatment at all. However, we cannot conclude whether one type of active treatment is more effective than another and there was no evidence of a difference in efficacy between oil-based and water-based active treatments.There is no evidence to show that using saline or water alone is better or worse than commercially produced cerumenolytics. Equally, there is also no evidence to show that using saline or water alone is better than no treatment.
Subject(s)
Cerumen , Ear Canal , Hygiene , Surface-Active Agents/therapeutic use , Adult , Antipyrine/therapeutic use , Benzocaine/therapeutic use , Carbamide Peroxide , Carbonates/therapeutic use , Child , Chlorobutanol/therapeutic use , Choline/analogs & derivatives , Choline/therapeutic use , Dioctyl Sulfosuccinic Acid/therapeutic use , Drug Combinations , Ethanolamines/therapeutic use , Humans , Peroxides/therapeutic use , Pharmaceutical Solutions/therapeutic use , Plant Oils/therapeutic use , Potassium/therapeutic use , Randomized Controlled Trials as Topic , Salicylates/therapeutic use , Sodium Chloride/therapeutic use , Urea/analogs & derivatives , Urea/therapeutic use , WaterABSTRACT
BACKGROUND/AIM: Even though polyethylene glycol-electrolyte lavage (PEG-EL)-based regimes have become the gold standard in recent years, to finish drinking 4 L of PEG-EL solution can be difficult. The quality of sennoside-based bowel-cleansing regimes used in Turkey has been known for some time. Therefore, we aimed to investigate the efficacy of both bowel-cleansing regimes. MATERIALS AND METHODS: Patients over 18 years old undergoing elective colonoscopic procedures between January and March 2011 were included in the study. The patients were divided into 2 groups; in Group 1, 91 patients were given sennoside a + b calcium 500 mg/250 mL (X-M solution, Yenisehir Laboratuari, Ankara, Turkey), and in Group 2, 94 patients were given 4 L of PEG-EL (Golytely, Boston, MA, USA). RESULTS: The mean age of the patients and the male distribution were similar in the 2 groups. Both inadequate bowel cleansing and the best cleansed bowels were seen in Group 1. The number of inadequate colonoscopies declined when using a whole bowel-cleansing regime from 24.5% to 19.3% in Group 2, but it did not decline in Group 1. CONCLUSION: The best bowel cleansing can be achieved with sennoside-based regimes, whereas a greater proportion of adequate results via colonoscopy were reached with the PEG-EL-based regimes.
Subject(s)
Colonic Diseases/diagnosis , Colonoscopy , Electrolytes/therapeutic use , Polyethylene Glycols/therapeutic use , Senna Extract/therapeutic use , Therapeutic Irrigation/methods , Adult , Cathartics/therapeutic use , Colonoscopy/methods , Colonoscopy/standards , Female , Humans , Male , Pharmaceutical Solutions/therapeutic use , Reproducibility of Results , Sennosides , Treatment OutcomeABSTRACT
There has been increased interest in the role of anti-Proteus antibodies in the aetiology of rheumatoid arthritis (RA) and whether chemotherapeutic agents active against Proteus species might reduce the risk and/or exacerbations of RA. We examined the in vitro antibacterial effects of ten different silver preparations which were either ionic silver [Ag(I)] solutions or nanoparticulate silver (NPS) (Ag(0)) suspensions against ATCC and two wild (clinical) strains of Proteus. The data establish the low minimum inhibitory concentration and minimum bactericidal concentration of all the silver formulations tested against these four Proteus strains. In a pilot study, a potent NPS preparation ex vivo showed long-lasting anti-Proteus activity in a normal human volunteer.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Arthritis, Rheumatoid/microbiology , Colloids/therapeutic use , Pharmaceutical Solutions/therapeutic use , Proteus/drug effects , Salts/therapeutic use , Silver/therapeutic use , Arthritis, Rheumatoid/etiology , Humans , Metal Nanoparticles/therapeutic use , Microbial Sensitivity Tests/methods , Pilot Projects , Suspensions/therapeutic useABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Geoffroea decorticans (chañar) fruits and their derivate product (arrope) have been traditionally used as food and a folk medicine for the treatment of a wide variety of diseases including bronchopulmonary disorders and to relieve dolorous process. AIM OF THE STUDY: In order to evaluate the pharmacology action of this plant, studies were performed of antinociceptive and antioxidant activities. MATERIALS AND METHODS: The aqueous and ethanolic extracts and arrope of chañar were evaluated in various established pain models, including chemical nociception induced by subplantar formalin and intraperitoneal acetic acid and thermal nociception method, such as tail immersion test in rats. To examine the possible connection of the opioid receptor to the antinociceptive activity of extracts and arrope it was performed a combination test with naloxone, a non-selective opioid receptor antagonist. RESULTS: The aqueous extract and arrope (1000 mg/kg) caused an inhibition of the pain in formalin test in the first phase, similar to morphine and decrease in the second phase. In a combination test using naloxone, diminished analgesic activity of aqueous extract and arrope were observed, indicating that antinociceptive activity is connected with the opioid receptor. The aqueous extract and arrope, caused an inhibition of the writhing response induced by acetic acid. Central involvement in analgesic profile was confirmed by the tail immersion test, in which the aqueous extract and arrope showed a significant analgesic activity by increasing latency time. The aqueous extract showed higher antioxidant activity than the arrope, it may be due to the cooking process. CONCLUSIONS: This study has shown that the aqueous extract and arrope of Geoffroea decorticans (chañar) fruits, does possess significant antinociceptive effects. It is further concluded that aqueous extract with maximum inhibition of free radical is the most potent extract amount tested extracts. At the oral doses tested the aqueous extract and arrope were non-toxic. The present results justifies their popular use and constitutes the first validation study of the antinociceptive action.
Subject(s)
Analgesics/therapeutic use , Fabaceae/chemistry , Fruit/chemistry , Herb-Drug Interactions , Naloxone/pharmacology , Pain/drug therapy , Phytotherapy/methods , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Analgesics/pharmacology , Animals , Antioxidants/pharmacology , Disease Models, Animal , Flavonoids/analysis , Male , Narcotic Antagonists , Pain/chemically induced , Pain Measurement/methods , Pharmaceutical Solutions/administration & dosage , Pharmaceutical Solutions/pharmacology , Pharmaceutical Solutions/therapeutic use , Phenols/analysis , Plant Extracts/administration & dosage , Plant Extracts/antagonists & inhibitors , Rats , Rats, WistarABSTRACT
Ear cleaning solutions are designed for repeated use, which raises the possibility for bacterial contamination leading to recurrent or persistent infectious otitis. The purpose of this study was to investigate the prevalence of bacterial contamination of commercial ear cleaners following routine home use in dogs and to describe the characteristics that are associated with contamination. Used ear cleaner bottles and information regarding their use were obtained from canine owners visiting veterinary dermatologists. Both the bottle applicator tips and the solution contents were cultured for aerobic bacteria. Bacterial contamination was present on 10% of the bottle tips and in 2% of the solutions. Isolated bacteria included Staphylococcus pseudintermedius, Bacillus spp., coagulase-negative Staphylococcus spp., Micrococcus spp. and Burkholderia cepacia. The contamination rate was significantly higher on the applicator tips than in the solutions (P = 0.0076). The applicator tip contamination rate was significantly higher in expired samples (17%) than in-date samples (4%; P = 0.0277). The bottle sizes were significantly larger for the samples with contaminated applicator tips compared with noncontaminated tips (P = 0.0455). The contamination rate was significantly higher when Tris-EDTA was an ingredient. Cleanliness of the bottle, contact with the ear canal and infection status of the ear at time of culture had no bearing on the contamination rate. In summary, with routine home use of commercial ear cleaners, pathogenic bacterial contamination is of minor concern. This concern may increase when expired products or larger bottles of ear cleaner are used and when Tris-EDTA is an ingredient.
Subject(s)
Dog Diseases/drug therapy , Equipment Contamination/statistics & numerical data , Otitis Externa/veterinary , Pharmaceutical Solutions/therapeutic use , Animals , Anti-Infective Agents, Local/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Bacillus/isolation & purification , Burkholderia cepacia/isolation & purification , Cerumenolytic Agents/therapeutic use , Chelating Agents , Dog Diseases/microbiology , Dogs , Drug Packaging , Edetic Acid , Micrococcus/isolation & purification , Otitis Externa/drug therapy , Otitis Externa/microbiology , Staphylococcus/isolation & purification , Surface-Active Agents/therapeutic useABSTRACT
BACKGROUND: We hypothesised that different solutions for submucosal injection may influence early healing of endoscopic mucosal resection (EMR). The aim of this study was to evaluate histological and immunological changes after EMR in experimental pigs. MATERIALS AND METHODS: Two parallel EMRs on the anterior and posterior wall of the gastric body were performed by means of the cap technique in 21 female pigs. A glycerol-based solution (anterior EMR) and hydroxypropyl methylcellulose solution (posterior EMR) were applied for submucosal injection. The animals were sacrificed 7 days later, and tissue sections of all EMRs were stained using combined trichrome. Computer image analysis was used for objective evaluation of elastic and collagen fibres content. Two-colour indirect immunophenotyping of blood and gastric samples were performed using mouse anti-pig monoclonal antibodies. RESULTS: The values of collagen fibre content 7 days after EMR were significantly higher in lesions after the use of solution A in comparison with solution B (2.10 +/- 0.25% versus 1.57 +/- 0.25%, p = 0.009). Concordant results were found in elastic fibres (3.23 +/- 0.49% versus 2.93 +/- 0.61%, p = 0.018). No systemic changes in major leukocyte subpopulations were found. In gastric tissue, lymphocyte subsets exhibited only minor changes. CD4(+) T-lymphocytes were increased in the healing tissue after EMR using solution A (17.08 +/- 9.24% versus 9.76 +/- 7.97%, p = 0.011). Significant increase of SWC3(+) leukocytes was observed after EMR using solution B (47.70 +/- 25.41% versus 18.70 +/- 12.16%, p = 0.001). CONCLUSIONS: The use of glycerol-based solution for submucosal injection was associated with more pronounced histological signs of early healing of EMRs compared with hydroxypropyl methylcellulose.
Subject(s)
Gastric Mucosa/drug effects , Gastroscopy , Glycerol/therapeutic use , Methylcellulose/analogs & derivatives , Pharmaceutical Solutions/therapeutic use , Wound Healing/drug effects , Animals , Collagen/analysis , Drug Evaluation, Preclinical , Elastic Tissue/pathology , Female , Gastric Mucosa/pathology , Gastric Mucosa/surgery , Glycerol/administration & dosage , Glycerol/pharmacology , Hypromellose Derivatives , Injections , Leukocytes/drug effects , Lymphocyte Subsets/drug effects , Methylcellulose/administration & dosage , Methylcellulose/pharmacology , Methylcellulose/therapeutic use , Pharmaceutical Solutions/administration & dosage , Pharmaceutical Solutions/pharmacology , Sus scrofa , Time Factors , ViscositySubject(s)
Complementary Therapies , Holistic Health , Otitis Media/therapy , Acute Disease , Adolescent , Bacterial Infections/complications , Child , Child, Preschool , Clinical Trials as Topic , Drugs, Chinese Herbal/administration & dosage , Drugs, Chinese Herbal/therapeutic use , Humans , Infant , Materia Medica , Osteopathic Medicine , Otitis Media/etiology , Otitis Media/microbiology , Pharmaceutical Solutions/therapeutic useABSTRACT
Next to dose concerns, the subject of preparation may be the most misinterpreted area of modem botanical medicine. Yet it is one of the most important issues in clinical practice. In traditional medicine systems, any given herb would have been discovered to be effective in specific preparations. The "ideal" form and preparation varies from herb to herb, as well as from person to person. The most desirable preparation is usually defined as the way to get the most active ingredient out of the herb. However, in some cases, the proper preparation may be the only way to safely use the herb. The proper preparation may be dictated by the solubility of the constituents and may also be defined according to how the patient is practicably able to consume it. In today's market, most herbs can be found in most preparations, but that does not mean that every preparation will contain active constituents. The author makes the case that using traditional preparations from the ethnic system of the herb origin will be the most effective clinical course of action.
Subject(s)
Plant Preparations/administration & dosage , Plant Preparations/chemistry , Chemistry, Pharmaceutical/methods , Dosage Forms , Humans , Nonprescription Drugs/classification , Nonprescription Drugs/therapeutic use , Ointments/classification , Ointments/therapeutic use , Pharmaceutical Solutions/chemistry , Pharmaceutical Solutions/classification , Pharmaceutical Solutions/therapeutic use , Phytotherapy/classification , Phytotherapy/standards , Plant Extracts/chemistry , Plant Extracts/classification , Plant Extracts/standards , Plant Preparations/classification , Plant Preparations/standards , Tea/classification , United StatesABSTRACT
OBJECTIVE: To determine a solution capable of discerning adipose versus nervous tissue, to aid in surgical separation of the adipose tissue which appears to be visually indistinguishable from nervous tissue in lipomyelomeningoceles (LMMs). METHODS: The following solutes (in normal saline) were investigated, both at 25 and 37 degrees C: beta-carotene, vitamin D, vitamin E, lecithin, hydrogen peroxide, lipase, protease, hyaluronidase, partially purified collagenase, purified collagenase, trypsin, trypsin plus purified collagenase and non-solute-containing saline (control). Each solution was applied to a pediatric lipoma to determine gross effects over a period of approximately 30 min. If a solution appeared to affect the adipose tissue grossly, studies of functional in vivo sensory evoked and spontaneous potentials using that particular solution were conducted upon sheep spinal cord, nerve roots, dura and peripheral nerve. Additionally, histological studies were conducted to determine the effect of that solution upon adipose tissue, spinal cord, myelin, dura and nerve roots. RESULTS: Of all solutions investigated, partially purified collagenase type 1 (T1C; Lot M0M4322, Code CLS-1, Worthington Biochemical Corporation, Lakewood, N.J., USA) at 37 degrees C was the most successful in grossly altering the consistency and appearance of adipose tissue. This change was more apparent over 20-30 min following application of the solution to the adipose tissue. Solutions not containing T1C did not show appreciable results; purified collagenase plus trypsin did not appear comparable or superior to T1C. No significant histological or functional change was noted when comparing the spinal cord, nerve rootlets, myelin, dura or peripheral nerve from the T1C-treated group versus normal (untreated) control groups. CONCLUSION: T1C appears to be a potentially effective solution for application during LMM surgery in the acute setting, and such use of an adjunct solution may significantly aid in the safe surgical resection of LMMs. Pending further research, this technique may be applied for other indications which require discernment or alteration of adipose versus nervous tissue.
Subject(s)
Adipose Tissue/drug effects , Adipose Tissue/pathology , Lipoma/pathology , Lipoma/surgery , Meningomyelocele/pathology , Meningomyelocele/surgery , Nerve Tissue/drug effects , Nerve Tissue/pathology , Pharmaceutical Solutions/chemistry , Pharmaceutical Solutions/pharmacology , Adipose Tissue/surgery , Chemotherapy, Adjuvant , Child , Collagenases/chemistry , Collagenases/pharmacology , Collagenases/therapeutic use , Humans , In Vitro Techniques , Lipoma/drug therapy , Meningomyelocele/drug therapy , Nerve Tissue/surgery , Pharmaceutical Solutions/therapeutic use , Time FactorsABSTRACT
Ciclopirox is a synthetic hydroxypyridone antifungal agent. In contrast to the azoles, glucuronidation is the main metabolic pathway of ciclopirox; therefore interactions with drugs metabolized via the cytochrome P450 system are unlikely Ciclopirox is also distinct from the common systemic agents, which interfere with sterol biosynthesis. In fact, ciclopirox chelates trivalent cations (such as Fe3+), inhibits metal-dependent enzymes that are responsible for degradation of toxic metabolites in the fungal cells, and targets diverse metabolic (eg, respiratory) and energy producing processes in microbial cells. Ciclopirox is a broad spectrum antimicrobial with activity against all the usual dermatophytes as well as yeast and nondermatophyte molds. It has demonstrated activity against gram positive and negative bacteria, including resistant strains of Staphlococcus aureus. Ciclopirox exhibits fungal inhibitory activity (minimum inhibitory concentration < 4 microg/mL for dermatophytes) as well as fungicidal activity; to date resistance to the drug has not been identified. Ciclopirox has been formulated in a nail lacquer delivery system. After evaporation of volatile solvents in the lacquer, the concentration of ciclopirox in the remaining lacquer film reaches approximately 35%, providing a high concentration gradient for penetration into the nail. Radiolabel data demonstrate penetration into infected nails after only 1 application of the lacquer. Ciclopirox nail lacquer is a topical product that provides an active fungicidal agent in a delivery system capable of promoting nail penetration. With repeated applications, the antifungal agent is homogeneously distributed through all layers of the toenail achieving concentrations of ciclopirox in excess of inhibitory and fungicidal concentrations for most pathogens. Although ciclopirox readily penetrates nails, very low levels of ciclopirox are recoverable systemically, even after chronic use. Ciclopirox nail lacquer 8% is a topical product that provides an active fungicidal agent in a delivery system capable of penetrating nails.